Member Directory - Executive Committee

Primary tabs

Chair: Charles Flexner

Objectives:

Create the scientific and programmatic agenda of LEAP to ensure a balanced and objective resource for those engaged in developing LA/ER agents for treatment and prevention of HIV, TB, and Hepatitis B & C.
Bring a broad representation including academic experts in LA/ER therapeutic drug development, community representatives, and non-governmental organizations (NGO’s) with an interest in supporting this field.
Serve as an honest broker to bridge gaps between academia, regulatory agencies, the pharmaceutical industry, and the community.

Charles W. Flexner, MD flex@jhmi.edu Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP). Conflict of Interest: Dr. Flexner reports receiving consulting income from Gilead Sciences, Merck, ViiV Healthcare, Janssen, and Theratechnologies. He also serves on a scientific advisory board for Navigen Corporation, and serves on a data safety and monitoring board for Advarra. He is a co-inventor on six issued patents related to long-acting drug delivery technology for HIV treatment and prevention.	Elaine J. Abrams, MD eja1@columbia.edu Dr. Abrams is a Professor of Epidemiology and Pediatrics at Columbia University and Senior Director for Research at ICAP. Conflict of Interest: Has no real or apparent conflicts of interest to report.
Robert Bollinger, MD, MPH rcb@jhmi.edu Dr. Bollinger is Founding Director of the Center for Clinical Global Health Education (CCGHE) and Professor of Infectious Diseases at the Johns Hopkins University (JHU) School of Medicine. Conflict of Interest: Receives royalties from emocha Health, miDiagnostics, consulting fees from Merck, Hologic, and grant funding from emocha Health.	Polly Clayden polly.clayden@i-base.org.uk Polly Clayden has been working as an advocate and activist for over 12 years and co-founded i-Base in April 2000 Conflict of Interest: Has no real or apparent conflicts of interest to report.
Paul L. Domanico, PhD pdomanico@clintonhealthaccess.org Dr. Paul L. Domanico holds a PhD in Chemistry and a Bachelor of Science degree in Pre-Medicine from Penn State University. He received his post-doctoral training in Molecular Biophysics at E.I. du Pont de Nemours and Co. Conflict of Interest: Has no real or apparent conflicts of interest to report.	Lobna Gaayeb, PhD lgaayeb@medicinespatentpool.org Lobna Gaayeb manages the Long-Acting Technologies project at the Medicines Patent Pool. She has experience in coordinating international networks and scientific projects. Conflict of Interest: Has no real or apparent conflicts of interest to report.
Rodney JY Ho, PhD, FAAPS, FAAS rodneyho@uw.edu Dr. Rodney JY Ho is a distinguished professor of pharmaceutics (SOP), adjunct professor of bioengineering (SOM) and is an inaugural presidential entrepreneurial fellow of the University of Washington. Conflict of Interest: No disclosures.	Daniel R. Kuritzkes, MD dkuritzkes@bwh.harvard.edu Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. Conflict of Interest: Receives consulting fees from AbbVie, Atea, Decoy, Gilead, GlaxoSmithKline, Jannsen, Merck, Moderna, Roche, Shionogi, ViiV. Receives consulting fees for non CME/CE service from Gilead, and research funding from, Merck, and ViiV. Has an ownership interest in Decoy..
Imelda Mahaka imahaka@pzat.org Imelda Mahaka is the Executive Director for Pangaea Zimbabwe AIDS Trust (PZAT). She provides strategic direction, overall oversight, coordination, and support for the implementation of PZAT programs. Conflict of Interest:	Mark Mirochnick, MD Mark.Mirochnick@bmc.org Mark Mirochnick, M.D. is Professor of Pediatrics and a member of the Division of Neonatology at Boston University School of Medicine/Boston Medical Center. Conflict of Interest: Dr. Mirochnick has salary support through his institution for research activities from Merck, ViiV and Gilead. His wife receives salary support for research activities through her institution from ViiV. He also receives consulting fees from AstraZeneca for his serving on the DSMBs for 2 of their protocols.
Adeniyi Olangunju, PhD olagunju@liverpool.ac.uk Dr Adeniyi Olagunju is a Senior Lecturer in the Department of Pharmacology and Therapeutics and a member of the Centre of Excellence for Long-acting Therapeutics (CELT), University of Liverpool, UK. Conflict of Interest: Has no real or apparent conflicts of interest to report.	Andrew Owen, PhD, FSB aowen@liverpool.ac.uk Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology and Director of the Centre of Excellence in Long-acting Therapeutics (CELT; www.liverpool.ac.uk/CELT) at the University of Liverpool. Conflict of Interest: Dr. Owen has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Tandem Nano Ltd., Gilead, Assembly Biosciences.
Kimberly Struble, PharmD Kimberly.Struble@fda.hhs.gov Kimberly Struble, PharmD, is a Senior Clinical Team Leader in the Division of Antiviral Products at the Food and Drug Administration. Conflict of Interest: None disclosed.	Susan Swindells, MBBS sswindells@unmc.edu Susan Swindells is a Professor of Internal Medicine in the Section of Infectious Diseases at the University of Nebraska Medical Center, USA. Conflict of Interest: Receives research grants to her institution from ViiV Healthcare.
David Thomas, MD, MPH dthomas@jhmi.edu David Thomas is Director of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine. Conflict of Interest: Has no real or apparent conflicts of interest to report.